Surufatinib+Toripalimab+GEMOX
Phase 2Small molecule
Surufatinib+Toripalimab+GEMOX is one of 56 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
69 competitors in Biliary Tract Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Imfinzi
AstraZenecaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Keytruda
Merck & Co.Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Adrucil
EElorac, Inc.
Phase 3
Herceptin
OOrganon and Co
Phase 3
Lytgobi
Taiho Oncology, Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFujian Cancer Hospital